Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Children Denied Immunizations At Increased Risk Of Whooping Cough
Children of parents who refuse vaccines are 23 times more likely to get whooping cough compared to fully immunized children, according to a new study led by a vaccine research team at Kaiser Permanente Colorado"s Institute for Health Research.

USA Today Examines 'Incendiary Debate' Over Abortion Rights
Nearly 40 years after the Supreme Court"s decision in Roe v. Wade, the "incendiary debate over abortion rights endures" and continues to manifest itself in a number of ways, USA Today reports. According to a recent USA Today/Gallup Poll, 78% of U.S. residents want abortion to be legal under at least some circumstances, with 21% saying it should be legal under any circumstance. According to the poll, 18% of respondents said that they want abortion always to be illegal. The poll also found that 46% of U.S. residents self-identify as "pro-choice," while 47% self-identify as "pro-life."Nancy Northup, president of the Center for Reproductive Rights, said, "The enduring divide represents the reality that there are fundamental religious differences on the issue of abortion that do not exist on, say, campaign finance or even on health care." Americans United for Life President Charmaine Yoest said that abortion-rights opponents are mobilizing to urge congressional lawmakers to exclude abortion coverage and funding from any federal health reform legislation.During the confirmation hearings of Supreme Court nominee Sonia Sotomayor, the judge said that she does not believe previous court rulings on abortion rights have ended the national controversy surrounding the issue. According to USA Today, Sotomayor, who has never ruled on the issue, declined to reveal her personal position on abortion rights. Several antiabortion-rights advocates also protested during Sotomayor"s hearings (Biskupic, USA Today, 7/24).In addition, the Center for Reproductive Rights this week released a report that found physicians and employees of health care clinics providing abortion services in six states -- Alabama, Mississippi, Missouri, North Dakota, Pennsylvania and Texas -- face an increasing level of harassment and death threats. The report was based on a four-month investigation (AP/Houston Chronicle, 7/23). The report was tied to the murder of Kansas abortion provider George Tiller (USA Today, 7/24). Operation Save America Director the Rev. Flip Benham, whose group is mentioned in the report, said the center is trying to limit the free-speech rights of abortion-rights opponents (AP/Houston Chronicle, 7/23).
News of the day
Document Examines Health Status Of Native American Indians Of Alabama
A newly published document, titled "Health Survey of American Indians of Alabama 2008:
Public Health

Advanced Life Sciences Announces Outcome Of FDA's Anti-Infective Drugs Advisory Committee Review Of Restanza(TM) (cethromycin)

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced that the FDA"s Anti-Infective Drugs Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). However, the committee voted that Restanza did not demonstrate efficacy in the treatment of CAP (3 positive, 11 negative, 1 abstaining). "We believe in Restanza"s potential and remain committed to its development. We were particularly encouraged by the supportive comments of several members of the committee relative to their positive review of the safety profile of Restanza, the therapeutic need for more effective treatments for CAP and their interest in seeing the company pursue further development," said Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences. "As we have throughout the review process we will continue to work closely with the FDA as they complete their assessment of the Restanza new drug application (NDA)." Although it is not binding, the Committee"s recommendation will be considered by the FDA as it completes its review of Restanza"s NDA in CAP. The FDA has established a Prescription Drugs User Fee Act (PDUFA) date of July 31, 2009 for the Restanza NDA. About Restanza Restanza is a novel, once-a-day, oral antibiotic that is under review for approval by the FDA for the treatment of CAP. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin-, macrolide-, and fluoroquinolone-resistant bacteria. Restanza"s demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CAP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication. About Community Acquired Pneumonia (CAP) CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. CAP affects 5.6 million patients in the United States each year, with 10 million physician visits and 2 million hospitalizations occurring annually. Macrolides and penicillins are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance. About Advanced Life Sciences Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer, respiratory diseases and biodefense. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences" filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise. Advanced Life Sciences Holdings, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009